Tempest Therapeutics Faces Nasdaq Delisting Warning
Ticker: TPST · Form: 8-K · Filed: Dec 31, 2024 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Dec 31, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: TPST
TL;DR
Nasdaq says TPST's stock price is too low, might get delisted.
AI Summary
On December 27, 2024, Tempest Therapeutics, Inc. filed an 8-K to report its receipt of a deficiency letter from The Nasdaq Stock Market LLC. The company failed to meet the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market.
Why It Matters
Failure to regain compliance with Nasdaq's minimum bid price rule could lead to the company's stock being delisted, significantly impacting its liquidity and investor accessibility.
Risk Assessment
Risk Level: high — The company is at high risk because it has received a deficiency letter from Nasdaq for failing to meet the minimum bid price requirement, which could lead to delisting.
Key Numbers
- $1.00 — Minimum Bid Price (Requirement for Nasdaq Capital Market continued listing)
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- The Nasdaq Stock Market LLC (company) — Listing Exchange
- $1.00 (dollar_amount) — Minimum bid price requirement
- December 27, 2024 (date) — Date of earliest event reported
FAQ
What is the primary reason for Tempest Therapeutics' 8-K filing?
Tempest Therapeutics filed an 8-K to report receiving a deficiency letter from The Nasdaq Stock Market LLC indicating non-compliance with the minimum bid price requirement for continued listing.
What specific listing rule did Tempest Therapeutics violate?
The company failed to meet the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 27, 2024.
What is the potential consequence of failing to meet the minimum bid price requirement?
The potential consequence is the delisting of Tempest Therapeutics' stock from the Nasdaq Capital Market.
What is the company's ticker symbol?
The ticker symbol for Tempest Therapeutics, Inc. is TPST, as indicated by the context of the filing and its former names.
Filing Stats: 709 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2024-12-31 16:01:33
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value TPST The Nasdaq Stock Mar
- $1.00 — Company's common stock had closed below $1.00 per share, the minimum closing bid pric
Filing Documents
- d848354d8k.htm (8-K) — 26KB
- 0001193125-24-287170.txt ( ) — 180KB
- tpst-20241227.xsd (EX-101.SCH) — 3KB
- tpst-20241227_def.xml (EX-101.DEF) — 13KB
- tpst-20241227_lab.xml (EX-101.LAB) — 22KB
- tpst-20241227_pre.xml (EX-101.PRE) — 14KB
- d848354d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEMPEST THERAPEUTICS, INC. Date:December 31, 2024 By: /s/ Stephen Brady Name: Stephen Brady Title: Chief Executive Officer